Journal article
The impact of statistical properties of incremental monetary net benefit and incremental cost-effectiveness ratio on health economic modeling choices
Abstract
INTRODUCTION: There is controversy on whether to use incremental monetary net benefit (INMB) or incremental cost-effectiveness ratio (ICER) in health economic evaluations alongside randomized controlled trials. We studied the impact of restricted mean survival time (RMST) on the long-term projection of INMB and ICER.
METHODS: We analyzed the unbiasedness and efficiency of ICER and INMB by (1) deriving the metrics' expected values and variances …
Authors
Yuan F; Bangdiwala SI; Tong W; Lamy A
Journal
Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 23, No. 1, pp. 69–78
Publisher
Taylor & Francis
Publication Date
January 2, 2023
DOI
10.1080/14737167.2023.2144838
ISSN
1473-7167